Clinical Trials Snapshot

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Cell Therapy Next, April 2019
Phase 1 trial to determine the safety for treatment of relapsed or refractory B cell lymphomas with CAR T-cells targeting cluster of differentiation…

Clinical Trials Snapshot

A Trial of “Armored” CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Cell Therapy Next, April 2019
Phase 1, open-label study testing the safety of different dose levels of specially prepared cells collected from the patient called “modified T…

Feature

‘We have to cure’ cancer, says CAR T pioneer Carl H. June, MD

April 18, 2019
Carl H. June , MD, is about to receive an award for his life’s work — it's not his first and it certainly won’t…

Point/Counter

Is ibrutinib-based therapy the preferred initial treatment for all patients with CLL?

HemOnc Today, April 10, 2019
POINT CLL is the most common leukemia among adults. Standard treatment is combination chemoimmunotherapy with regimens such as chlorambucil plus…

Cover Story

Advances in chronic lymphocytic leukemia suggest progress is ‘visible on the horizon’

HemOnc Today, April 10, 2019
The transition from primarily chemotherapy-based approaches to targeted therapies revolutionized treatment of chronic lymphocytic leukemia, the most…

Meeting News

Cost of cancer care under scrutiny, projected to keep rising

April 7, 2019
ORLANDO — The market for cell therapy has drastically evolved over the last several years, leading to new reimbursement strategies for…

Meeting News

CAR T-cell therapy pioneer Carl H. June, MD, awarded 2019 Harrington Prize

April 5, 2019
The American Society for Clinical Investigation has recognized Carl H. June, MD, as the recipient of its sixth annual Harrington Prize in…

Feature

Trial explores T-cell therapy’s role in personalized treatment for lung cancer

April 4, 2019
ATLANTA — In the battle against non-small cell lung cancer, the ability to personalize treatment may be a key to victory, according to Karen

Meeting NewsPerspective

Autologous cell vaccine prolongs survival in newly diagnosed glioblastoma

April 1, 2019
ATLANTA — An autologous cell vaccine composed of glioblastoma tumor cells and an antisense molecule against insulin-like growth factor type 1…

Meeting NewsPerspective

HER2-targeted CAR T cells safely induce responses in advanced HER2-positive sarcoma

March 31, 2019
ATLANTA — Adults and children with advanced HER2-positive sarcoma safely tolerated and derived clinical benefit from lymphodepletion…

Meeting NewsPerspective

CAR T-cell therapy shows promise for mesothelin-expressing solid tumors

March 31, 2019
ATLANTA — Intrapleurally administered, mesothelin-targeted chimeric antigen receptor T cells demonstrated antitumor activity without major…

Feature

ASH president: Society is ‘extremely committed’ to continuing advocacy for NIH funding

March 26, 2019
Roy L. Silverstein, MD, began his 1-year term as ASH president in January. Silverstein — who will serve in that position through the end of…

Point/Counter

Will CAR T cells become first-line therapy for hematologic malignancies?

HemOnc Today, March 25, 2019
POINT CAR T cells have already changed the treatment paradigm for recurrent and resistant DLBCL, which, as shown in the SCHOLAR-I study, has a dismal…

Cover Story

New indications may accelerate ‘explosion’ in CAR T-cell therapy, but more education still needed

HemOnc Today, March 25, 2019
Years of research into chimeric antigen receptor T-cell therapy for cancer treatment is finally paying dividends. When Renier J. Brentjens, MD

Meeting News

Experts debate CAR T-cell therapy vs. transplant for relapsed diffuse large B-cell lymphoma

March 23, 2019
NEW YORK — Chimeric antigen receptor T-cell therapy confers better outcomes than autologous stem cell transplant to some patients with relapsed…

CAR T-cell therapy changing the landscape of lymphoma treatment

March 23, 2019
NEW YORK — Chimeric antigen receptor T cell therapies could be the breakthrough hematologists have sought to effectively treat certain patients…

In the Journals

Inflammatory markers linked to neurotoxicity severity after CAR T-cell infusion for DLBCL

March 20, 2019
Neurotoxicity from chimeric antigen receptor T-cell therapy appeared associated with cytokine release syndrome, with blood levels of cytokines and…

FDA accepts new drug application for liver cancer T-cell therapy

January 30, 2019
Eureka Therapeutics announced that the FDA has cleared its investigational new drug application for ET140202 ARTEMIS T-cell therapy for patients with…

Feature

Association of American Cancer Institutes launches initiative to advance CAR T-cell therapies

January 22, 2019
Association of American Cancer Institutes launched a national initiative to advance the use of chimeric antigen receptor T-cell therapies. The…

Feature

Trial to assess CAR T-cell therapy for HER2-positive metastatic breast cancer

January 19, 2019
Researchers at City of Hope have opened a first-in-human clinical trial to assess the use of chimeric antigen receptor T-cell therapy for patients…